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A B S T R A C T
We present two cases of daptomycin-induced eosinophilic pneumonia with characteristic chest x ray, CT scan
and bronchoalveolar lavage (BAL) findings. It is not a commonly seen complication of Daptomycin but when it
happens, it could cause a diagnostic and treatment dilemma. Patients could present acutely with hypoxic re-
spiratory failure or a less dramatic chronic presentation is also possible. Our two patients presented with acute
hypoxic respiratory failure and presentation resembles that of an infectious etiology. Diagnosis is confirmed by
bronchoscopy with BAL in one of them and the other was treated empirically as the clinical and radiologic
presentation was typical. Treatment includes removal of the offending agent, daptomycin. Corticosteroids are
used if symptoms are severe and can result in rapid clinical improvement. There is no agreed upon dose and
duration of steroids and we suggest a long taper of steroids for patients who present with severe symptoms and a
short course steroid for patients with milder symptoms.
Eosinophilic pneumonia (EP) represents a spectrum of disease from
a mild transient process to severe interstitial fibrosis. It is characterized
by pulmonary infiltrates and increased numbers of eosinophils in
Broncho-alveolar lavage (BAL) fluid, with or without increased levels of
eosinophils in the peripheral blood [1,2]. Several medications have
been reported to cause eosinophilic pulmonary opacities and acute
eosinophilic pneumonia. Nonsteroidal anti-inflammatory drugs and
antibiotics are mainly implicated [3]. The pathophysiology of EP is not
clearly known but it is hypothesized that it is related to T helper 2
lymphocytes recruitment by alveolar macrophages and release of in-
terleukin 5 which promotes eosinophil production and migration to the
lung. Production of a potent eosinophil chemoattractant by macro-
phages also is considered to have an effect on the pathophysiology
[2,4]. Daptomycin is an intravenous cyclic lipopeptide antibiotic with a
spectrum of activity similar to vancomycin. It is FDA-approved for
complicated skin, skin structure and blood stream infections caused by
gram-positive organisms, including both methicillin-susceptible and
resistant strains of Staphylococcus aureus, including patients with right-
sided infective endocarditis [3,5]. It was initially approved for skin and
soft tissue infections and it is now being used to treat more serious
infections involving the blood stream and the endocardium and is ex-
pected to be used more frequently. Eosinophilic pneumonia has been
reported with daptomycin in post marketing in 2007 [6]. Daptomycin is
distributed into lung tissue; however, it is inhibited by pulmonary
surfactant and this daptomycin-surfactant interaction was also hy-
pothesized to change the lipid integrity and induces an inflammatory
response seen in daptomycin induced eosinophilic pneumonitis [4]. A
case of eosinophilic pneumonia most likely associated with daptomycin
was defined as meeting all of the following criteria, Concurrent ex-
posure to daptomycin, Fever, Dyspnea with increased oxygen require-
ment or requiring mechanical ventilation, New infiltrates on chest x-ray
or computed tomography scan, Bronchoalveolar lavage with>25%
eosinophils, and Clinical improvement following daptomycin with-
drawal [6].
It is not a common complication, but it requires prompt recognition
since it can be associated with respiratory failure and potentially fatal
outcome. As health professionals use this medication more frequently,
daptomycin induced eosinophilic pneumonia is expected to increase in
prevalence and physicians should have a high index of suspicion of the
condition and treat it accordingly. We present two cases of daptomycin
induced eosinophilic Pneumonitis.
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1. Case 1
The first case is a 68-year-old white male, a retired welder, who was
seen at infectious disease clinic when he was remaining with 2 more
weeks of a 6 week course of Daptomycin/Rifampin. He had staphylo-
coccus epidermidis septic arthritis and was placed on Vancomycin but
developed significant renal toxicity and was placed on Daptomycin and
Rifampin. The patient reported dry cough with occasional production of
clear sputum, low grade fever but denied skin rash or joint swelling.
On examination vital signs were stable except for a low-grade fever
of 100.3 and SPO2 of 89% that dropped down further to 84% upon
ambulation. Fine basilar crackles were auscultated bilaterally but no
murmurs, JVD or leg edema were observed.
CXR showed bilateral ill-defined opacities more on the left side as
shown in the x ray picture. High resolution CT scan showed interstitial
and ground glass opacities.
Laboratory studies revealed WBC of 5700/mcl, with 11% of eosi-
nophils, hemoglobin level of 9.9 g/dl, platelet count of 364,000/mcl and
creatinine level of 1.63mg/dl. His CRP level was 34.1, ESR of 25 with a
total CK level of 92. ABGs showed a PH of 7.51, PCO2 of 30 and PO2 of
63. He was admitted and placed on a high flow oxygen. Daptomycin-
induced pneumonitis was suspected. Bronchoscopy was done with BAL
showing 28% eosinophils. He was continued on steroids with significant
improvement. He was discharged home with a long taper and less
oxygen requirements. Reevaluation after 4 weeks showed significant
improvement of dyspnea and no more need for supplemental
CXR Before the treatment
CXR after the treatment
HRCT at admission
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HRCT after 4 weeks on long prednisone taper.
2. Case 2
The second case is a 71-year-old male patient who was sent from
another facility for evaluation of dyspnea, cough, fever and diaphoresis.
He was discharged earlier on IV daptomycin to complete 6 weeks of
treatment. Diagnosis of Health care associated pneumonia was en-
tertained for which he was started on antibiotics along with
Daptomycin. He required 2L of nasal cannula oxygen. Vital signs were
stable except for a temperature 100 F. The SaO2 was 92% on 2L oxygen.
He had decreased breath sounds in the lower lung field bilaterally with
fine crackles. He had no raised JVP, murmurs, gallop or peripheral
edema. Laboratory studies showed a WBC count of 6500/mcl with a
6.4% eosinophil, hemoglobin level of 9.6 g/dl, platelet count of
134,000/mcl and creatinine level of 1.28 mg/dl. Procalcitonin was 0.26
ng/ml and Chest HRCT revealed an upper lobe bilateral infiltrates.
Daptomycin was stopped and patient was placed on steroids resulting in
improvement of his symptoms and resolution of hypoxemia.
3. Discussion
In 2007, pulmonary eosinophilia was added to the Adverse
Reactions, Post-Marketing Experience section of the Daptomycin product
label. Since then, the Agency has reviewed published case reports of
Daptomycin-associated eosinophilic pneumonia, and conducted a re-
view of post-marketing adverse event reports from the FDA's Adverse
Event Reporting System (AERS). FDA's review identified 7 definite, 13
probable and 38 possible cases of eosinophilic pneumonia between
2004 and 2010 that were most likely associated with Daptomycin as
[3,4] (see Table 1).
Our first patient fits into class of a definite case of daptomycin in-
duced EP and the second one into category of a probable case. In
general, patients developed eosinophilic pneumonia 2 to 4 weeks after
starting daptomycin. But it could come earlier than that [8,9]. Our two
patients presented to the hospital between the 3rd and 4th week after
starting daptomycin and health care professionals should look for this
complication any time after daptomycin is started.
According to literature, 87% of patients were Male and the mean
age of patients is 65.4 a standard deviation of 15 years [2]. Old age and
male sex are dominant risk factors for EP and that was observed in our 2
patients. It is shown in a review that the adverse effect does not appear
to be dose dependent but time dependent exposure. Daptomycin dose
and duration of administration were not significant risk factors for EP
[2,5]. The patients in our report are getting 6 and 8 mg/kg/dose every
24 hours and it is very difficult to reach to a conclusion on the re-
lationship of dose, duration of antibiotics and side effect from the 2
patients in our review and this might need further study for better ex-
planation.
Dyspnea was the most common documented symptom associated
with eosinophilic pneumonia followed by the presence of either pul-
monary infiltrates or opacities on chest x-ray or CT [2]. Both of our
patients had dyspnea and pulmonary infiltrates on the CT, but EP pa-
tients might present with fever in the absence of respiratory symptoms
[5,10,11]. EP may or may not be associated with peripheral blood eo-
sinophilia, however pulmonary eosinophilic infiltrates or BAL eosino-
philia are the corner stone for the diagnosis of EP. A lung biopsy can
verify the diagnosis but is not always a requisite given a typical clinical
appearance and consistent laboratory and radiographic findings
[12–14].
Most patients with DIEP respond to discontinuation of the drug but
some patients might have severe respiratory symptoms and might need
treatment with steroids and respiratory assistance [2,5]. In both of our
patients we used steroids and the response is dramatic. Steroids act by
Table 1
Criteria for inclusion as definite, probable, possible, and unlikely cases of daptomycin-induced eosinophilic pneumonia [6,7].
Definite Probable Possible Unlikely
Concurrent exposure to daptomycin Concurrent exposure to daptomycin Concurrent exposure to daptomycin All other cases that did
not meet criteria
Dyspnea with increased oxygen requirement or
requiring mechanical ventilation
Dyspnea with increased oxygen requirement or
requiring mechanical ventilation
New infiltrates on CXR or CT
New infiltrates on CXR or CT New infiltrates on chest x-ray or CT Clinical improvement following daptomycin
withdrawal OR the patient died
BAL with > 25% eosinophils BAL with≤25% eosinophils OR peripheral
eosinophilia
Clinical improvement following daptomycin
withdrawal
Clinical improvement following daptomycin
withdrawal
Fever
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programmed cell death and accelerating intracellular signaling re-
sulting in death of eosinophils [2].
In the first patient we started him with methylprednisolone 60mg IV
Q6H and that was changed to 40mg PO prednisolone daily and it was
tapered in 4 weeks. In our second case, presentation was milder so we
started the patient with 60mg IV methylprednisolone which was
changed to 40mg PO prednisone to be continued for 5 days. Both pa-
tients were stable when they were seen after they finish their steroid
treatment. Our 1st patient was needing up to 5 L of oxygen and was
discharged with 3L but when he came back after a month, he was sent
home without oxygen. Our second patient was needing 2L of oxygen
and he was not needing any oxygen at discharge. Both clinical and
radiologic improvement after the cessation of daptomycin administra-
tion and steroid treatment was dramatic.
4. Conclusion
Daptomycin is being used extensively by infectious disease specia-
lists and ICU physicians. Its indications are being extended from time to
time because of its excellent antimicrobial activity and coverage.
Because of this, the relatively rare complication of DIEP is expected to
rise significantly proportional to use of daptomycin. Life threatening
respiratory failure can happen if the diagnosis is missed and appro-
priate treatment not instituted. Physicians should make themselves
aware of this condition and properly treat these patients.
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